Mark Pruzanski's most recent trade in Equillium Inc was a trade of 20,000 Director Stock Option (right to buy) done . Disclosure was reported to the exchange on May 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 20,000 | 20,000 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 24,000 | 0 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 24,000 | 24,000 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 20,770 | 0 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 20,770 | 20,770 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 20,000 | 0 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 20,000 | 20,000 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 12,000 | 0 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 12,000 | 12,000 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 17.21 per share. | 30 Nov 2021 | 6,138 | 622,711 (1%) | 0% | 17.2 | 105,635 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.21 per share. | 30 Nov 2021 | 3,817 | 618,894 (1%) | 0% | 17.2 | 65,691 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 16.86 per share. | 29 Oct 2021 | 6,138 | 620,390 (1%) | 0% | 16.9 | 103,487 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.86 per share. | 29 Oct 2021 | 3,817 | 616,573 (1%) | 0% | 16.9 | 64,355 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 14.85 per share. | 30 Sep 2021 | 6,136 | 618,068 (1%) | 0% | 14.9 | 91,120 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.85 per share. | 30 Sep 2021 | 3,816 | 614,252 (1%) | 0% | 14.9 | 56,668 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 14.91 per share. | 31 Aug 2021 | 6,138 | 615,749 (1%) | 0% | 14.9 | 91,518 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.91 per share. | 31 Aug 2021 | 3,817 | 611,932 (1%) | 0% | 14.9 | 56,911 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 17.28 per share. | 30 Jul 2021 | 6,138 | 613,428 (1%) | 0% | 17.3 | 106,065 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.28 per share. | 30 Jul 2021 | 3,817 | 609,611 (1%) | 0% | 17.3 | 65,958 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 19.97 per share. | 30 Jun 2021 | 6,136 | 611,106 (1%) | 0% | 20.0 | 122,536 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.97 per share. | 30 Jun 2021 | 3,816 | 607,290 (1%) | 0% | 20.0 | 76,206 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 16.63 per share. | 28 May 2021 | 6,138 | 608,787 (1%) | 0% | 16.6 | 102,075 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.63 per share. | 28 May 2021 | 3,817 | 604,970 (1%) | 0% | 16.6 | 63,477 | Common Stock |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 20,770 | 20,770 | - | - | Stock Option (right to buy) | |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 19.78 per share. | 30 Apr 2021 | 6,138 | 506,466 (1%) | 0% | 19.8 | 121,410 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.78 per share. | 30 Apr 2021 | 3,817 | 502,649 (1%) | 0% | 19.8 | 75,500 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 23.08 per share. | 31 Mar 2021 | 6,136 | 503,986 (1%) | 0% | 23.1 | 141,619 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.08 per share. | 31 Mar 2021 | 3,658 | 500,328 (1%) | 0% | 23.1 | 84,427 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 21.66 per share. | 26 Feb 2021 | 6,138 | 500,591 (1%) | 0% | 21.7 | 132,949 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.66 per share. | 26 Feb 2021 | 2,741 | 497,850 (1%) | 0% | 21.7 | 59,370 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 35.24 per share. | 29 Jan 2021 | 6,138 | 497,194 (1%) | 0% | 35.2 | 216,303 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.24 per share. | 29 Jan 2021 | 2,741 | 494,453 (1%) | 0% | 35.2 | 96,593 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.08 per share. | 01 Oct 2020 | 772 | 475,517 (1%) | 0% | 42.1 | 32,486 | Common Stock |